Question Everything. See who's reporting it.

Tirzepatide tops India’s GLP-1 market with 62% share

Source: Indian Express

The story in brief

Injectable tirzepatide and semaglutide, launched in 2025, have dominated India’s GLP-1 market, with tirzepatide accounting for Rs 1,456 crore (62%) and semaglutide contributing Rs 782 crore (34%). The market is stabilizing after a surge driven by generics, which made the drugs more affordable.

NEWXFree on Android and iPhone. Open in NEWX